MACOM’s beat was small, but the capacity signal is the tradable part

The first conclusion is that this was not a “beat and raise” story in the usual sense, because the actual beat was deliberately modest: EPS was $0.94 versus the Street at $0.93, a +1.2% surprise, and revenue was $261.2 million versus $260.2 million, a +0.4% surprise. That matters because investors could have priced in a record quarter after revenue had already moved from $218.1 million in Q1 FY2025 to $235.9 million in Q2 FY2025 and $252.1 million in Q3 FY2025. What the market likely had in the model was continued sequential growth and some benefit from mix; what it may be underpricing is that MACOM is now linking incremental capacity, inventory build, and gross margin progression in one operating plan rather than treating capacity as a cost headwind. The print itself cleared a low upside bar, but the guide and balance sheet behavior suggest the next debate is whether FY2026 revenue and margin are capacity-limited or demand-limited.

That distinction is visible in the trajectory. Revenue reached $261.2 million in Q4 FY2025, up +3.6% sequentially and +30.1% year-over-year, while gross margin was 54.6%, above the 53.7% in Q3 FY2025 and below the 57.6% peak seen in Q4 FY2023. The quarter therefore did not prove that MACOM has fully recovered prior margin structure, but it did prove the company can keep revenue growing while margins move higher from the Q1 FY2025 trough of 51.2%. The company’s own adjusted framework is more favorable than the GAAP series in the history table: CFO John Kober said, “Adjusted gross profit for fiscal Q4 was $149.1 million or 57.1% of revenue.” That wording matters because management is asking investors to value the forward model on adjusted gross margin, and the Q1 guide of 56.5% to 58.5% brackets that Q4 adjusted level rather than resetting lower as capacity spending rises.

The capacity story explains why the margin guide is more important than the revenue beat, because inventory and capex are moving before the revenue appears. Inventories were $237.8 million at quarter end, up from $215.4 million, and Kober tied that specifically to “additional work-in-process inventory at the RTP Fab” and higher balances to support anticipated demand. Capex also stepped up to $20.2 million in fiscal Q4, up $11.5 million sequentially, while fiscal year 2026 CapEx is estimated at $50 million to $55 million after fiscal year 2025 CapEx of $42.6 million. The bear read is that working capital and capex are rising into a slowing sequential revenue cadence, since revenue growth decelerated from +8.1% in Q2 FY2025 to +6.9% in Q3 FY2025 and +3.6% in Q4 FY2025. The variant read is that MACOM is creating capacity ahead of a margin-accretive demand mix, because management simultaneously guided Q1 FY2026 revenue to $265 million to $273 million and adjusted EPS to $0.98 to $1.02, based on 76.6 million fully diluted shares.

The strongest piece of evidence for that variant read is management’s willingness to quantify capacity rather than simply promise scale. Kober said the equipment plan should “allow us to expand our RTP Fab capacity and capabilities by up to 30% over the next 12 to 18 months.” That is the sentence the market should care about more than the +0.4% revenue surprise, because it sets a time window and a capacity magnitude against which future bookings, inventory, and margin can be judged. If the company were merely chasing revenue, the margin guide would likely absorb the cost of the expansion. Instead, the company guided adjusted gross margin to 56.5% to 58.5% for fiscal Q1 and separately said it expects sequential quarterly gross margin improvements of between 25 to 50 basis points as it moves through fiscal 2026. Those two data points create a testable framework: capacity spending should not prevent margin expansion if utilization and mix arrive as planned.

The end-market mix supports that interpretation, but only with precision. Stephen Daly said Q4 end-market revenue was Industrial & Defense at $115.6 million, Telecom at $66 million, and Data Center at $79.6 million. The investor temptation is to frame MACOM as a pure data center connectivity story, especially after management highlighted design work in 300 and 400-gig per lane connectivity ICs for future 1.6T and 3.2T systems. The numbers argue for a broader and less fragile thesis: Industrial & Defense was the largest Q4 bucket at $115.6 million, Data Center was $79.6 million, and Telecom was $66 million. That mix matters because a capacity addition at RTP does not need a single end-market to carry the model. It also makes the sequential margin guide more credible, since all 3 end markets contributed to the Q4 record according to Kober, while Q1 guidance implies revenue above Q4 without forcing an abrupt dependence on one customer program.

The balance sheet is the other reason the capacity build should be read as offensive rather than stressed. Daly said, “We generated $193 million in free cash flow, and we finished the year with approximately $786 million in cash and short-term investments on our balance sheet.” Kober also said cash flow from operations increased by 45% to $235.4 million for fiscal 2025, and Q4 cash flow from operations was approximately $69.6 million, up $9.2 million sequentially and more than $7.3 million over fiscal Q4 2024. The company does have a near-term use of cash, with $161 million of principal value of remaining March 2026 notes expected to be paid off over the next couple of quarters. But the numbers indicate that the FY2026 CapEx estimate of $50 million to $55 million and the note repayment are not mutually exclusive claims on a thin balance sheet. That is central to the thesis: MACOM can fund capacity while preserving optionality, so the market should not automatically haircut the margin guide for balance sheet risk.

The call delivery also leaned in the direction of confidence, though not without one conflict investors should monitor. The tone history shows Q4 FY2025 sentiment at 0.49, above Q3 FY2025 at 0.34 and Q2 FY2025 at 0.41, while prepared_sentiment rose to 0.77 from 0.52 in Q3 FY2025. Guidance_tone was 0.49, slightly below 0.52 in Q3 FY2025 and below 0.50 in Q2 FY2025, so management’s scripted delivery was more positive than its guidance language. That split fits the financial message: the company was confident about the completed year and capacity plan, but it did not overstate the near-term guide after a modest Street beat. The later tone history reinforces that this was not a one-call anomaly: by Q2 FY2026, sentiment was 0.47, guidance_tone was 0.69, prepared_sentiment was 0.78, and qa_sentiment was 0.27. The conflict is uncertainty, which rose to 77.7 in Q4 FY2025 from 66.5 in Q3 FY2025, so confidence in the prepared story came with more uncertainty in the transcript. That is not fatal to the thesis, but it argues for watching inventory conversion rather than just listening for optimism.

That tone setup is consistent with the reported versus Street distinction. On the Street-comparison basis, revenue was $261.2 million versus $260.2 million and EPS was $0.94 versus $0.93. On the company’s own full-year account, Daly said, “For the full year, FY '25 revenue was $967 million, more than a 32% increase year-over-year, and EPS was $3.47, more than a 35% increase year-over-year.” Those are different uses of the numbers: the former tells us the quarter did not materially outpace sell-side models, while the latter tells us management is positioning FY2025 as the base for a larger revenue platform. Daly made that explicit by saying the Q1 FY2026 guide would allow MACOM to achieve its $1 billion annual revenue goal on a trailing 12-month basis. The important investment point is not the milestone itself; it is that the company is trying to cross it while guiding Q1 adjusted gross margin to 56.5% to 58.5%, not by accepting a gross margin reset.

The supply-chain read-through is therefore concentrated in capacity and substrate demand rather than named customer upside, because the data pack lists no customers of MACOM. For suppliers, the RTP Fab and connectivity roadmap are incrementally relevant to GlobalFoundries, linked to Silicon photonics L-PIC on 90WG 300mm, and to WIN Semiconductors for GaAs MMIC wafers. The SiC substrate chain also has a measurable implication: SICC supplies SiC substrates and TanKeBlue supplies 6-inch SiC substrates at approximately $500/wafer. The magnitude to anchor is MACOM’s planned capacity expansion of up to 30% over the next 12 to 18 months and FY2026 CapEx of $50 million to $55 million, not the +0.4% revenue surprise. If MACOM follows through, those suppliers should see demand tied to production equipment, wafer flow, and substrate requirements before the revenue impact fully appears in MACOM’s reported sales.

The peer comparison helps frame why the stock reaction should focus on margin durability, not just growth. In the Analog_Sensors peer table, MACOM’s latest reported quarter shows $289.0 million in revenue, 56.9% gross margin, and +22.5% revenue YoY. That gross margin is below ADI at 67.3% but above SLAB at 56.7%, QRVO at 48.9%, ALGM at 47.1%, SWKS at 40.8%, HIMX at 30.4%, and 6479.T at 18.3%. MACOM’s +22.5% revenue YoY trails ADI’s +37.2% and ALGM’s +26.1%, but it is ahead of SLAB’s +20.1%, 6479.T’s +15.3%, SWKS at -1.0%, QRVO at -7.0%, and HIMX at -7.2%. That places MACOM in a narrower but more valuable lane than the headline beat suggests: it is not the fastest grower in the peer set, but it combines above-midpack growth with gross margin already near the higher-quality end of the group. The market’s mistake would be to treat MACOM as a small-cap cyclical analog name after an in-line quarter rather than as a margin-expanding capacity story with a defined fab bottleneck.

The risk to that view is not hard to identify. Sequential revenue growth slowed to +3.6% in Q4 FY2025 after +6.9% in Q3 FY2025 and +8.1% in Q2 FY2025, while inventories rose to $237.8 million from $215.4 million. Depreciation expense also increased to $8.7 million in fiscal Q4 2025 from $6.9 million in Q3 2025, and capex rose to $20.2 million from the prior quarter by $11.5 million. If demand does not arrive, those numbers turn from forward investment into operating leverage pressure. The offset is that adjusted operating income was $67 million, up 5.5% sequentially from $63.5 million in fiscal Q3 2025 and up 32.1% year-over-year, while adjusted net income increased approximately 4.7% to $71.4 million from $68.2 million. The operating data do not yet show the cost of expansion overwhelming the model. They show a company taking on capacity costs while still expanding adjusted profit dollars.

What to watch next is precise. For fiscal Q1 ending January 2, 2026, the thesis requires revenue within or above the $265 million to $273 million guide, adjusted gross margin within or above 56.5% to 58.5%, and adjusted EPS within or above $0.98 to $1.02 on 76.6 million fully diluted shares. It also requires management to maintain the fiscal 2026 message of sequential quarterly gross margin improvements of between 25 to 50 basis points, because that is the clearest evidence that the RTP Fab expansion is not dilutive. The break points are equally concrete: inventories rising materially above $237.8 million without revenue progressing beyond $261.2 million, capex moving beyond the $50 million to $55 million fiscal year 2026 estimate without a clearer revenue ramp, or a retreat from the up to 30% RTP Fab capacity expansion over the next 12 to 18 months. Confirmation would be Q1 revenue near the high end of $265 million to $273 million with adjusted gross margin near the high end of 56.5% to 58.5%; failure would be a revenue guide miss paired with inventory still building from $237.8 million, because that would convert today’s variant perception from capacity-led upside into demand-risk overbuild.